| 10/07/23 | 07:00:07 | 10 Jul 2023 | | Phase 1 Study of HMPL-415 Initiated |
| 29/06/23 | 09:30:00 | 29 Jun 2023 | | Blocklisting Six Monthly Return |
| 26/06/23 | 09:30:01 | 26 Jun 2023 | | HUTCHMED to Announce 2023 Half-Year Results |
| 16/06/23 | 07:00:05 | 16 Jun 2023 | | Phase III FRESCO-2 Results in The Lancet |
| 15/06/23 | 15:39:19 | 15 Jun 2023 | | MAA of Fruquintinib Validated by the EMA |
| 09/06/23 | 10:30:03 | 9 Jun 2023 | | HUTCHMED Highlights Presentations at EHA and ICML |
| 06/06/23 | 10:00:01 | 6 Jun 2023 | | LTIP and Share Option Scheme |
| 31/05/23 | 09:30:00 | 31 May 2023 | | Total Voting Rights |
| 26/05/23 | 07:00:06 | 26 May 2023 | | Fruquintinib NDA Granted Priority Review by FDA |
| 26/05/23 | 07:00:06 | 26 May 2023 | | HUTCHMED Highlights Presentations at ASCO 2023 |
| 17/05/23 | 09:30:02 | 17 May 2023 | | Standard form for notification of major holdings |
| 12/05/23 | 13:15:01 | 12 May 2023 | | Annual General Meeting Poll Results |
| 12/05/23 | 09:30:01 | 12 May 2023 | | Board of Directors and Board Committee Membership |
| 10/05/23 | 09:30:01 | 10 May 2023 | | Appointment of Independent NED |
| 28/04/23 | 09:30:01 | 28 Apr 2023 | | Total Voting Rights |
| 21/04/23 | 09:30:00 | 21 Apr 2023 | | Vesting of awards under the LTIP |
| 18/04/23 | 07:00:07 | 18 Apr 2023 | | NDA Acceptance in China for Fruquintinib |
| 12/04/23 | 07:00:07 | 12 Apr 2023 | | Presentations at AACR Annual Meeting 2023 |
| 11/04/23 | 09:30:02 | 11 Apr 2023 | | Intended Retirement of Independent NED |
| 11/04/23 | 09:30:02 | 11 Apr 2023 | | 2022 Annual Report and Notice of AGM |
| 04/04/23 | 10:30:01 | 4 Apr 2023 | | HUTCHMED Initiates Registration Phase Enrollments |
| 31/03/23 | 09:30:01 | 31 Mar 2023 | | Total Voting Rights |
| 31/03/23 | 07:00:11 | 31 Mar 2023 | | Rolling Submission of Fruquintinib US NDA Complete |
| 14/03/23 | 13:30:01 | 14 Mar 2023 | | Closing of Fruquintinib License to Takeda |
| 08/03/23 | 08:30:02 | 8 Mar 2023 | | Director's Share Dealing |
| 06/03/23 | 08:30:02 | 6 Mar 2023 | | Vesting of awards under the LTIP |
| 28/02/23 | 12:15:02 | 28 Feb 2023 | | Publication of Form 20-F |
| 28/02/23 | 08:30:01 | 28 Feb 2023 | | 2022 Full Year Results and Business Updates |
| 27/02/23 | 10:00:05 | 27 Feb 2023 | | Enrollment Completed in Phase 2 Amdizalisib trial |
| 31/01/23 | 08:30:02 | 31 Jan 2023 | | Notice of Results |
| 23/01/23 | 08:00:01 | 23 Jan 2023 | | License to Takeda for Fruquintinib outside China |
| 18/01/23 | 14:30:02 | 18 Jan 2023 | | Inclusion of ORPATHYS in NRDL in China |
| 03/01/23 | 08:30:01 | 3 Jan 2023 | | Enrollment Completed in Phase 3 Trial |
| 30/12/22 | 08:30:05 | 30 Dec 2022 | | Blocklisting Six Monthly Return |
| 19/12/22 | 10:00:01 | 19 Dec 2022 | | FDA NDA Rolling Submission for Fruquintinib |
| 15/11/22 | 07:00:05 | 15 Nov 2022 | | HUTCHMED Announces Strategy Update |
| 14/11/22 | 07:00:06 | 14 Nov 2022 | | Positive Topline Phase 3 Result in Fruquintinib |
| 27/10/22 | 12:30:01 | 27 Oct 2022 | | HUTCHMED Initiates Phase 2/3 Trial of Fruquintinib |
| 21/10/22 | 09:30:00 | 21 Oct 2022 | | Vesting of awards under the LTIP |
| 10/10/22 | 09:30:06 | 10 Oct 2022 | | Phase II/III Trial of Sovleplenib for in China |
| 30/09/22 | 09:30:05 | 30 Sept 2022 | | Total Voting Rights |
| 14/09/22 | 11:00:05 | 14 Sept 2022 | | Share Option Scheme and Long Term Incentive Plan |
| 08/09/22 | 07:00:06 | 8 Sept 2022 | | FRESCO-2 Colorectal Cancer MRCT Data Highlights |
| 23/08/22 | 10:00:04 | 23 Aug 2022 | | Holding(s) in Company |
| 23/08/22 | 09:30:06 | 23 Aug 2022 | | HUTCHMED To Present FRESCO-2 Data at ESMO 2022 |
| 09/08/22 | 09:30:06 | 9 Aug 2022 | | First Participant in Phase I Trial of IMG-004 |
| 08/08/22 | 09:30:05 | 8 Aug 2022 | | Preliminary results from SAVANNAH Phase 2 Trial |
| 08/08/22 | 07:00:06 | 8 Aug 2022 | | FRESCO-2 Study Has Met Primary Endpoint |
| 01/08/22 | 12:04:30 | 1 Aug 2022 | | Interim Results and Business Updates |
| 01/08/22 | 07:00:12 | 1 Aug 2022 | | HUTCHMED Initiates Bridging Study of Tazemetostat |
